VOZRIA Trademark

Trademark Overview


On Friday, January 8, 2021, a trademark application was filed for VOZRIA with the United States Patent and Trademark Office. The USPTO has given the VOZRIA trademark a serial number of 79306175. The federal status of this trademark filing is REGISTERED as of Tuesday, November 9, 2021. This trademark is owned by Glaxo Group Limited. The VOZRIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, immunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disorders, namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), hpv, rsv, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, ...
vozria

General Information


Serial Number79306175
Word MarkVOZRIA
Filing DateFriday, January 8, 2021
Status700 - REGISTERED
Status DateTuesday, November 9, 2021
Registration Number6549771
Registration DateTuesday, November 9, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 24, 2021

Trademark Statements


Goods and ServicesPharmaceutical preparations for use as anti-infectives; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), human papilloma virus, respiratory syncytial virus, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of respiratory diseases and disorders and their symptoms; pharmaceutical preparations for the treatment of immune system related diseases and disorders, namely, immunosuppressants; pharmaceutical preparations for the treatment of immunologic diseases and disorders, namely, autoimmune diseases and disorders; pharmaceutical preparations for the treatment of atherosclerosis; pharmaceutical preparations for the treatment of viral conditions, namely, human immunodeficiency virus (hiv), hpv, rsv, hepatitis, herpes genitalis, herpes labialis, herpes simplex virus, varicella-zoster virus, epstein-barr virus and cytomegalovirus; pharmaceutical preparations for the treatment and prevention of metabolic related diseases and disorders, namely, disorders of the endocrine system, namely, growth and thyroid disorders, diabetes, metabolic syndrome, obesity, weight loss and weight management; pharmaceutical preparations for the treatment and prevention of cardiovascular, cardiopulmonary, cardio-renal and renal diseases and disorders; pharmaceutical preparations for the prevention and treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of inflammation and inflammatory related diseases and disorders, namely, arthritis, rheumatoid arthritis, inflammatory bowel diseases, inflammatory connective tissue diseases, vasculitis, synovitis; pharmaceutical preparations for the prevention and treatment of sequelae of oncologic diseases and their treatment, namely, nausea and vomiting, hematologic depression, mucositis, cachexia, pain, bone pain and fatigue; pharmaceutical preparations for the treatment of blood-related diseases and disorders, namely, thrombocytopenia, coagulation disorders, bleeding disorders, platelet disorders, blood vessel disorders, sickle-cell disease and its related disorders, anemias, sepsis and infections in and of the blood; pharmaceutical preparations for the treatment of musculoskeletal diseases, disorders and injuries, namely, connective tissue diseases, bone diseases, osteoporosis, spinal diseases, back pain, gout, fractures, sprains, sports injuries, osteogenesis imperfecta, muscle wasting (cachexia), renal osteodystrophy, cartilage injuries, joint replacement and osteoarthritis; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the treatment of dermatological diseases and disorders, namely, dermatitis, skin and skin structure infections, namely, bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections, psoriasis, eczema and sexually transmitted diseases; pharmaceutical preparations for the treatment of hormonal related diseases and disorders, namely, hypogonadism, testosterone/androgen disorders and estrogen disorders; pharmaceutical preparations for the treatment of gastrointestinal related diseases and disorders, namely, irritable bowel disorders and symptoms, digestive disorders and acid-related disorders; pharmaceutical preparations for the treatment of sexual dysfunction, namely, erectile dysfunction, male and female sexual dysfunction disorders, namely, arousal disorder, pain disorder, desire disorder and orgasm disorder; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases and disorders; pharmaceutical preparations for the treatment of gynaecological diseases and disorders, namely, amenorrhoea, dysmenorrheal and infertility; pharmaceutical hormonal preparations, namely, corticosteroids, hormone replacement therapy preparations, oral contraceptives, thyroid hormone preparations; pharmaceutical preparations for the treatment of incontinence, prostate diseases and disorders, bladder diseases and disorders; pharmaceutical preparations for the treatment of sexually transmitted diseases, inflammatory pelvic diseases, vasomotor/menopausal symptoms, endometriosis/uterine fibroids, leiomyoma, endourology/stone, pre-eclampsia and pre-term labour; pharmaceutical preparations for the treatment of prostatitis, nephritis, cystitis, vaginitis, renal disease; pharmaceutical preparations for the treatment of premenstrual dysphoric disorder, premenstrual syndrome, male hypogonadism and hormonal disorders, namely, polycystic ovary syndrome; pharmaceutical preparations for the treatment of hepatological related diseases, namely, hepatitis, non-alcoholic fatty liver disease (nafld), non-alcoholic steatohepatitis (nash), liver fibroids, and cirrhosis; pharmaceutical preparations for the treatment of alopecia and androgenic alopecia (male pattern baldness); pharmaceutical preparations for the treatment of psychiatric diseases and disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, and psychoses; pharmaceutical preparations for the treatment of damaged skin and tissue, namely, bee stings, sunburn, rashes, sores, corns, calluses and acne; pharmaceutical preparations for the treatment of inflammatory connective tissue diseases and injuries; pharmaceutical preparations for the treatment of malaria; pharmaceutical preparations for the treatment of tuberculosis; allergy medications; vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, March 15, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGlaxo Group Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressGB

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressGB

Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressGB

Trademark Events


Event DateEvent Description
Sunday, July 30, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Saturday, March 12, 2022NOTIFICATION PROCESSED BY IB
Wednesday, February 23, 2022FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, February 22, 2022FINAL DISPOSITION PROCESSED
Thursday, December 9, 2021GRANT OF PROTECTION CREATED, TO BE SENT TO IB
Tuesday, November 9, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, August 24, 2021PUBLISHED FOR OPPOSITION
Sunday, August 22, 2021NOTIFICATION PROCESSED BY IB
Wednesday, August 4, 2021NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, August 4, 2021NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 4, 2021NOTICE OF PUBLICATION
Tuesday, July 20, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, July 19, 2021ASSIGNED TO EXAMINER
Friday, March 19, 2021APPLICATION FILING RECEIPT MAILED
Monday, March 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, March 12, 2021LIMITATION FROM ORIGINAL APPLICATION ENTERED
Thursday, March 11, 2021SN ASSIGNED FOR SECT 66A APPL FROM IB